上诉法院维持辉瑞因新冠药物与Enanta的专利胜利

2026-06-24 00:29

A federal appeals court has sided with Pfizer (PFE) in a patent dispute with Enanta Pharmaceuticals (ENTA) over the pharma giant’s COVID-19 therapy Paxlovid.
The Court of Appeals for the Federal Circuit ruled that a lower court was correct in issuing a summary judgment against Enanta (ENTA) in a dispute over the U.S. Patent No. 11,358,953, which related to coronavirus protease inhibitors.
Enanta (ENTA) filed a lawsuit in 2022 in a Massachusetts federal court seeking damages from Pfizer (PFE), which it said violated the ’953 patent during the development and commercialization of the COVID-19 pill.
In December 2024, the U.S. District Court for the District of Massachusetts ruled in favor of Pfizer (PFE), noting that the ’953 patent that Enanta (ENTA) claimed to have received in 2022 was invalid, prompting the company to file an appeal.

More on Pfizer, Enanta Pharma